Related Experiment Video

Updated: May 7, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.4K

Simultaneous blockade of the CD73/EGFR axis inhibits tumor growth

Keivan Ardeshiri1, Hadi Hassannia2,3, Ghasem Ghalamfarsa4

  • 1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

IUBMB Life
|January 2, 2025
PubMed

Insights

Simultaneously targeting CD73 and epidermal growth factor receptor (EGFR) using nanocarriers effectively reduced breast cancer cell death and tumor growth. This combined approach shows promise as a novel cancer immunotherapy strategy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Nanotechnology

Background:

  • Tumor microenvironment factors significantly influence cancer progression, immune evasion, and therapeutic resistance.
  • Combined targeting of cooperating factors offers greater efficacy than single-agent therapies.
  • CD73 and EGFR are key factors in tumor growth, exhibiting mutual stimulation of expression and function.

Purpose of the Study:

  • To investigate the efficacy of co-delivering anti-CD73 and anti-EGFR siRNAs using previously characterized nanocarriers.
  • To evaluate the impact of silencing the CD73/EGFR axis on murine breast cancer 4T1 cells and tumor growth.

Main Methods:

  • Utilized nanocarriers for targeted delivery of siRNA against CD73 and EGFR.
  • Assessed the effects of siRNA delivery on 4T1 cell viability, migration, and proliferation.
  • Evaluated the therapeutic effect in an in ovo tumor growth model.

Main Results:

  • Silencing CD73 and EGFR significantly induced cancer cell death.
  • Downregulation of the CD73/EGFR axis suppressed cancer cell migration and proliferation.
  • The combined therapeutic strategy inhibited tumor growth in the in ovo model.

Conclusions:

  • Simultaneous targeting of CD73 and EGFR is a potent strategy against breast cancer.
  • This approach warrants further investigation as a novel immunotherapeutic strategy.
Keywords:
4T1CD73EGFRbreast cancercancer therapynanoparticles

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K